Metadata

Name Cancer immunotherapy medication
Type Disease or Syndrome
Group Disease or Syndrome
Data Sources
Clinical Terminologies British National Formulary
Codelists
Valid Event Data Range 01/01/1999 - 01/07/2019
Sex Female
Male
Authors Lai A.
Agreement Date 1 Mar 2019
Version (UUID) 1 (Vkf6SPU4ig6A4ARJkYnP2r)

Primary care

prodcode prodname drugsubstance bnfcode strength
25740 Avastin 100mg/4ml solution for infusion vials (Roche Products Ltd) Bevacizumab 8010500 25mg/1ml
27292 Herceptin 150mg powder for concentrate for solution for infusion vials (Roche Products Ltd) Trastuzumab 8010500 150mg
28490 Rituximab 100mg/10ml solution for infusion vials Rituximab 08020300/10010301 10mg/1ml
31076 Trastuzumab 150mg powder for solution for infusion vials Trastuzumab 8010500 150mg
31598 MabCampath 30mg/3ml concentrate for solution for infusion ampoules (Schering Health Care Ltd) Alemtuzumab 0 10mg/1ml
32712 Erbitux 100mg/50ml solution for infusion vials (Merck Serono Ltd) Cetuximab 0 2mg/1ml
33205 Cetuximab 100mg/50ml solution for infusion vials Cetuximab 0 2mg/1ml
36294 Rituximab 500mg/50ml solution for infusion vials Rituximab 08020300/10010301 10mg/1ml
38145 Bevacizumab 100mg/4ml solution for infusion vials Bevacizumab 8010500 25mg/1ml
38158 Cetuximab 100mg/20ml solution for infusion vials Cetuximab 8010500 5mg/1ml
39111 Rituximab 10mg/ml concentrated intravenous infusion Rituximab 08020300/10010301 10mg/ml
42273 Alemtuzumab 30mg/1ml solution for infusion vials Alemtuzumab 8020300 30mg/1ml
44004 Denosumab 60mg/1ml solution for injection pre-filled syringes Denosumab 6060200 60mg/1ml
44084 Prolia 60mg/1ml solution for injection pre-filled syringes (Amgen Ltd) Denosumab 6060200 60mg/1ml
45122 Panitumumab 100mg/5ml solution for infusion vials Panitumumab 8010500 20mg/1ml
47502 MabThera 100mg/10ml concentrate for solution for infusion vials (Roche Products Ltd) Rituximab 08020300/10010301 10mg/1ml
54058 Denosumab 120mg/1.7ml solution for injection vials Denosumab 6060200 70mg/1ml
55815 MabCampath 30mg/1ml concentrate for solution for infusion vials (Genzyme Therapeutics Ltd) Alemtuzumab 8020300 30mg/1ml
56041 Ipilimumab 50mg/10ml solution for infusion vials Ipilimumab 8010500 5mg/1ml
58018 Xgeva 120mg/1.7ml solution for injection vials (Amgen Ltd) Denosumab 6060200 70mg/1ml
58142 Brentuximab vedotin 50mg powder for solution for infusion vials Brentuximab vedotin 8010500 50mg
58819 Herceptin 600mg/5ml solution for injection vials (Roche Products Ltd) Trastuzumab 8010500 120mg/1ml
58862 Ipilimumab 200mg/40ml solution for infusion vials Ipilimumab 8010500 5mg/1ml
59276 Erbitux 100mg/20ml solution for infusion vials (Merck Serono Ltd) Cetuximab 8010500 5mg/1ml
61908 Pertuzumab 420mg/14ml solution for infusion vials Pertuzumab 8010500 30mg/1ml
66436 Cetuximab 500mg/100ml solution for infusion vials Cetuximab 8010500 5mg/1ml
69589 Alemtuzumab 12mg/1.2ml solution for infusion vials Alemtuzumab 8020500 10mg/1ml
70553 Obinutuzumab 1g/40ml solution for infusion vials Obinutuzumab 8020500 25mg/1ml
71157 Nivolumab 100mg/10ml solution for infusion vials Nivolumab 8010500 10mg/1ml
71269 Pembrolizumab 100mg/4ml solution for infusion vials Pembrolizumab 8010500 25mg/1ml
72094 Truxima 500mg/50ml concentrate for solution for infusion vials (Napp Pharmaceuticals Ltd) Rituximab 08020300/10010301 10mg/1ml
72422 Avelumab 200mg/10ml solution for infusion vials Avelumab 8010500 20mg/1ml
73083 Lemtrada 12mg/1.2ml concentrate for solution for infusion vials (Genzyme Therapeutics Ltd) Alemtuzumab 8020500 10mg/1ml
73295 Trastuzumab 600mg/5ml solution for injection vials Trastuzumab 8010500 120mg/1ml
73503 Rixathon 100mg/10ml concentrate for solution for infusion vials (Sandoz Ltd) Rituximab 08020300/10010301 10mg/1ml
74553 Truxima 100mg/10ml concentrate for solution for infusion vials (Napp Pharmaceuticals Ltd) Rituximab 08020300/10010301 10mg/1ml

Publications

  • Lai A. et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. DOI: 10.1101/2020.05.27.20083287

  • Banerjee A. et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. The Lancet. DOI: 10.1016/S0140-6736(20)30854-0